Pregravid preparation, pregnancy and childbirth, especially the course of the postpartum period in patients with multiple sclerosis (literature review)

Cover Page

Abstract


Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the formation of lesions in the white matter as a result of autoimmune inflammation, neurodegeneration and demyelination and leading to severe disability of patients. Women get sick more often than men; young women of reproductive age account for about 2/3 of all MS patients. It was established that pregnancy and childbirth with MS have a beneficial effect on the course of the disease, however, patients with MS need pregravid preparation, which will reduce the risk of exacerbations. Exacerbations are observed in most cases during the first 3–6 months of the postpartum period, which is associated with a change in hormonal status, emotional and physical stress on the woman’s body, and also with the cessation of physiological immunosuppression in a pregnant woman. The analysis of modern literature sources on the issues of pregravid preparation, pregnancy and childbirth, and the features of postpartum period in multiple sclerosis, as well as new ideas concerning the disease etiology and pathogenesis. 47 literature sources (national and foreign) were analyzed using various databases (PubMed, PubMed Central, Google Scholar, UpToDate).


Full Text

Restricted Access

About the authors

Anastasia D. Kupina

Rostov State Medical University

Author for correspondence.
Email: anastasya1997@bk.ru
ORCID iD: 0000-0003-1676-4649

Russian Federation, Rostov-on-Don

Clinical Resident

Yuriy A. Petrov

Rostov State Medical University

Email: mr.doktorpetrov@mail.ru
ORCID iD: 0000-0002-2348-8809

Russian Federation, Rostov-on-Don

D. Sci. (Med.), Prof.

References

  1. Парфенов В.А., Яхно Н.Н., Евзиков Г.Ю. Нервные болезни. Учебник. М.: Медицинское информационное агентство, 2018. [Parfenov V.A., Yakhno N.N., Evzikov G.Yu. Nervous Diseases. A Textbook. Moscow: Meditsinskoe informatsionnoe agentstvo, 2018 (in Russian).]
  2. Морозова С.Н., Брюхов В.В., Трифонова О.В. и др. Поражение спинного мозга у пациентов с рассеянным склерозом после обострения по данным диффузионно-тензорной магнитно-резонансной томографии. Журн. неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2016; 116 (2): 21–6. https://doi.org/10.17116/jnevro20161162221-26 [Morozova S.N., Bryukhov V.V., Trifonova O.V. et al. A DTI study of the spinal cord lesion in patients with multiple sclerosis during the follow-up after relapse. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. Spetsvypuski. 2016; 116 (2): 21–6. https://doi.org/10.17116/jnevro20161162221-26 (in Russian).]
  3. Прожерина Ю. Рассеянный склероз: история, диагностика, лечение. Ремедиум. 2016; 8 (7): 21–5. [Prozherina Yu. Multiple sclerosis: history, diagnosis, treatment. Remedium. 2016; 8 (7): 21–5 (in Russian).]
  4. Kumar V, Abbas A, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease. Saunders Elsevier Publ 2014; p. 1473–5.
  5. Malik O, Donnelly A, Barnett М. Fast Facts Multiple Sclerosis. Health Press Ltd Publ. 2014; 136.
  6. Fourcade J, Sun Z, Kudela P et al. Human tumor antigen-specific helper and regulatory T-cells share common epitope specificity but exhibit distinct T-cell repertoire. J Immunology 2010; 184 (12): 6709–18. https://doi.org/ 10.4049/jimmunol.0903612
  7. Gelfand JM. Multiple sclerosis: diagnosis, differential diagnosis, and clinical presentation. Handbook Clin Neurol 2014; 122: 269–90. https://doi.org/10.1016/B978-0-444-52001-2.00011-X
  8. Mullin AP, Cui Ch,Wang Yu et al. rHIgM22 enhances remyelination in the brain of the cuprizone mouse model of demyelination. Neurobiol Dis 2017; 105: 142–55. https://doi.org/10.1016/j.nbd.2017.05.015
  9. Plemel JR, Liu WQ, Yong WV. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nature Reviews Drug Discovery 2017; 16: 617–34. https://doi.org/10.1038/nrd.2017.115
  10. Губарев Ю.Д., Яценко Е.А., Чефранова Ж.Ю. Клиническая эффективность препарата «Азилект» в терапии вторично-прогрессирующего рассеянного склероза. Научный результат. 2015; 1 (4): 5–12. https://doi.org/10.18413/2313-8955-2015-1-4-5-12 [Gubarev Yu.D., Yatsenko E.A., Chefranova Zh.Yu. Clinical efficiency of Azilekt in the therapy of primary progressing multiple sclerosis. Nauchnyi rezul’tat. 2015; 1 (4): 5–12. https://doi.org/10.18413/2313-8955-2015-1-4-5-12 (in Russian).]
  11. Alamouti MA, Bakhtiyari M, Moradi F et al. Remyelination of the corpus callosum by olfactory ensheathing cell in an experimental model of multiple sclerosis. Acta Medica Iranica 2015; 53 (9): 533–9.
  12. Atlas of multiple sclerosis 2013. http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
  13. Баранов А.А., Намазова-Баранова Л.С. Атлас редких болезней. ФГБУ «Научный центр здоровья детей» РАМН. М.: ПедиатрЪ, 2013; c. 304. [Baranov A.A., Namazova-Baranova L.S. Atlas of rare diseases. FSBI «Scientific Center for Children’s Health» RAMS. Moscow: Pediatr»», 2013; p. 304 (in Russian).]
  14. Langer-Gould A, Brara SM, Beaber BE, Koebnick C. Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome. Neurology 2013; 80 (6): 548–52. https://doi.org/10.1212/WNL.0b013e3182a7af5f
  15. Чжу М.Б. Коморбидность при рассеянном склерозе. Молодой ученый. 2018; 44: 225–7. [Chzhu M.B. Multiple Sclerosis Comorbidity. Molodoi uchenyi. 2018; 44: 225–7 (in Russian).]
  16. Ширинский В.С., Ширинский И.В. Коморбидные заболевания – актуальная проблема клинической медицины. Сиб. мед. журн. 2014; 29 (1): 7–12. https://doi.org/10.29001/2073-8552-2014-29-1-7-12 [Shirinskii V.S., Shirinskii I.V. Comorbid diseases as an important problem of clinical medicine. Sib. med. zhurn. 2014; 29 (1): 7–12. https://doi.org/10.29001/2073-8552-2014-29-1-7-12 (in Russian).]
  17. O’Gorman C, Bukhari W, Todd A et al. Smoking increases the risk of multiple sclerosis in Queensland, Australia. J Clin Neurosci 2014; 21 (10): 1730–3. https://doi.org/10.1016/j.jocn.2014.01.009
  18. Wang Z, Sadovnick AD, Traboulsee AL et al. Nuclear Receptor NR1H3 in Familial Multiple Sclerosis. Neuron 2016; 92 (2): 555. https://doi.org/10.1016/j.neuron.2016.09.028
  19. Ghasemi N, Razavi Sh, Nikzad E. Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell Journal 2017; 19 (1): 1–10. https://doi.org/10.22074/cellj.2016.4867
  20. Коробко Д.С., Малкова Н.А., Соколова Е.А., Филипенко М.Л. Фенотип и генотип семейного рассеянного склероза. Медицина и образование в Сибири. 2012; 6. http://ngmu.ru/cozo/mos/article/text_full.php?id=853 [Korobko D.S., Malkova N.A., Sokolova E.A., Filipenko M.L. Phenotype and genotype of familial multiple sclerosis1cbgh. Meditsina i obrazovanie v Sibiri. 2012; 6 (in Russian).]
  21. Bäärnhielm M, Olsson T, Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis. Multiple Sclerosis J 2014; 20 (6): 726–32. https://doi.org/10.1177/1352458513509508
  22. Bilbaoa MM, Durána SB, Llonaa JB, Rodriguez-Antigüedad A. Multiple sclerosis: pregnancy and women’s health issues. Neurologia 2019; 34 (4): 259–69. https://doi.org/10.1016/j.nrleng.2016.06.014
  23. Шарова И.В., Куташов В.А. Рассеянный склероз, беременность и роды. Медицина: вызовы сегодняшнего дня: материалы III Международной научной конференции. М.: Буки-Веди, 2016; c. 57–60. [Sharova I.V., Kutashov V.A. Multiple sclerosis, pregnancy and childbirth. Medicine: today’s challenges: proceedings of the III International Scientific Conference. Moscow: Buki-Vedi, 2016; p. 57–60 (in Russian).]
  24. Тихоновская О.А., Кочеткова А.Ю., Алифирова В.М. Особенности репродуктивного здоровья женщин, больных рассеянным склерозом. Acta Biomedica Scientifica. 2017; 2 (5): 26–31. [Tikhonovskaya O.A., Kochetkova A.Yu., Alifirova V.M. The features of reproductive health in women with multiple sclerosis. Acta Biomedica Scientifica. 2017; 2 (5): 26–31 (in Russian).]
  25. McCombe PA. The Short and Long-Term Effects of Pregnancy on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. J Clin Med 2018; 7 (12): 494. https://doi.org/10.3390/jcm7120494
  26. Якушина Т.И., Котов С.В., Якушин М.А. Анализ течения беременности, родов и послеродового периода у женщин с рассеянным склерозом. Альманах клинической медицины. 2015; 39: 82–8. https://doi.org/10.18786/2072-0505-2015-39-82-89 [Yakushina T.I., Kotov S.V., Yakushin M.A. Analysis of the course of pregnancy, delivery and postpartum period in women with multiple sclerosis. Al’manakh klinicheskoi meditsiny. 2015; 39: 82–8. https://doi.org/10.18786/2072-0505-2015-39-82-89 (in Russian).]
  27. Шмидт Т.Е. Ранняя диагностика рассеянного склероза. Рус. мед. журн. Неврология. 2010; 18 (5): 224. [Shmidt T.E. Early diagnosis of multiple sclerosis. Rus. med. zhurn. Nevrologiya. 2010; 18 (5): 224 (in Russian).]
  28. Карнаух В.Н., Барабаш И.А. Является ли беременность фактором риска рассеянного склероза? Влияние на прогноз. Дальневосточный мед. журн. 2010; 1: 131–4. [Karnaukh V.N., Barabash I.A. Is pregnancy a risk factor of multiple sclerosis? Its influence on the prognosis of the disease. Dal’nevostochnyi med. zhurn. 2010; 1: 131–4 (in Russian).]
  29. Радзинский В.Е., Фукс А.М. Гинекология. Учебник. М.: ГЭОТАР-Медиа, 2014. [Radzinskii V.E., Fuks A.M. Gynecology. A textbook. Moscow: GEOTAR-Media, 2014 (in Russian).]
  30. Шмидт Т.Е., Яхно Н.Н.. Рассеянный склероз. Руководство для врачей. М.: МЕДпресс-информ, 2016. [Shmidt TE, Yakhno NN. Multiple sclerosis: a guideline. Moscow: MEDpress-inform, 2016 (in Russian).]
  31. Houtchens MK, Edwards NC, Schneider G et al. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology 2018; 91 (17): e1559–e1569. https://doi.org/10.1212/WNL.0000000000006384
  32. Zhang X, Hay JW, Niu X. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-b1a in relapsing-remitting multiple sclerosis. CNS Drugs 2015; 29 (1): 71–81. https://doi.org/10.1007/s40263-014-0207-x
  33. Alwan S, Yee I, Dybalski M et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Multiple Sclerosis J 2013; 19: 351–8. https://doi.org/10.1177/1352458512452920
  34. Hutchinson M, Fox RJ, Havrdova E et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Cur Med Res Opin 2014; 30 (4): 613–27. https://doi.org/10.1185/03007995.2013.863755
  35. Спирин Н.Н., Касаткин Д.С., Степанов И.О. и др. Побочные эффекты терапии препаратами, изменяющими течение рассеянного склероза (ПИТРС), по данным регистра рассеянного склероза Ярославской области. Журн. неврологии и психиатрии им. С.С. Корсакова. 2012; 112 (8): 27–33. [Spirin N.N., Kasatkin D.S., Stepanov I.O. et al. Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2012; 112 (8): 27–33 (in Russian).]
  36. Lu E, Wang BW, Guimond C et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Exp Rev Neurotherapeutics 2013; 13 (3): 251–60. https://doi.org/10.1586/ern.13.12
  37. Prosperini L, Pontecorvo S. Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clinical Risk Management 2016; 12: 339–50. https://doi.org/10.2147/TCRM.S85099
  38. Tavazzi E, Rovaris M, Mantia LL. Drug therapy for multiple sclerosis. Canadian Med Assoc J 2014; 186 (11): 833–40. https://doi.org/10.1503/cmaj.130727
  39. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Multiple Sclerosis J 2013; 19: 835–43. https://doi.org/10.1177/1352458512471880
  40. Sena A, Couderc R, Vasconcelos JC et al. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci 2012; 317 (1–2): 47–51. https://doi.org/10.1016/j.jns.2012.02.033
  41. Gava G, Bartolomei I, Costantino A et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril 2014; 102 (1): 116–22. https://doi.org/10.1016/j.fertnstert.2014.03.054
  42. Кочеткова А.Ю., Тихоновская О.А., Алифирова В.М. Влияние комбинированных оральных контрацептивов на течение рассеянного склероза. Современные проблемы науки и образования. 2015; 6. http://www.science-education.ru/ru/article/view?id=22818 [Kochetkova A.Yu., Tikhonovskaya O.A., Alifirova V.M. The effect of combined oral contraceptives on the course of multiple sclerosis. Sovremennye problemy nauki i obrazovaniya. 2015; (6). http://www.science-education.ru/ru/article/view?id=22818 (in Russian).]
  43. Попова Е.В., Кукель Т.М., Муравин А.И. и др. Ретроспективный анализ течения беременности и родов у женщин с рассеянным склерозом. Журн. неврологии и психиатрии им. С.С. Корсакова. 2013; 113 (10): 52–6. [Popova E.V., Kukel’ T.M., Muravin A.I. et al. Pregnancy and delivery in women with multiple sclerosis: a retrospective analysis. Zhurn. nevrologii i psikhiatrii im. S.S. Korsakova. 2013; 113 (10): 52–6 (in Russian).]
  44. Finkelsztejn A, Brooks JBB, Paschoal FM, Fragoso YD. What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and metaanalysis of the literature. BJOG 2011; 118 (7): 790–7. https://doi.org/10.1111/j.1471-0528.2011.02931.x
  45. Муравин А.И., Бойко А.Н., Попова Е.В., Мурашко А.В. Влияние беременности на течение рассеянного склероза. Мед. совет. 2015; 7: 23–7. [Muravin A.I., Boiko A.N., Popova E.V., Murashko A.V. Effect of pregnancy on the course of multiple sclerosis. Med. sovet. 2015; 7: 23–7 (in Russian).]

Statistics

Views

Abstract - 92

PDF (Russian) - 42

Cited-By


PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies